PMID- 36946485
OWN - NLM
STAT- MEDLINE
DCOM- 20230911
LR  - 20240302
IS  - 1875-6190 (Electronic)
IS  - 1570-159X (Print)
IS  - 1570-159X (Linking)
VI  - 21
IP  - 11
DP  - 2023
TI  - Update on Cannabidiol Clinical Toxicity and Adverse Effects: A Systematic Review.
PG  - 2323-2342
LID - 10.2174/1570159X21666230322143401 [doi]
AB  - BACKGROUND: Compelling evidence from preclinical and clinical studies supports 
      the therapeutic role of cannabidiol (CBD) in several medical disorders. We 
      reviewed the scientific evidence on CBD-related toxicity and adverse events (AEs) 
      in 2019, at the beginning of the spike in clinical studies involving CBD. 
      However, CBD safety remained uncertain. OBJECTIVE: With the benefit of hindsight, 
      we aimed to provide an update on CBD-related toxicity and AEs in humans. METHODS: 
      A systematic literature search was conducted following PRISMA guidelines. PubMed, 
      Cochrane, and Embase were accessed in October 2022 to identify clinical studies 
      mentioning CBDrelated toxicity/AEs from February 2019 to September 2022. Study 
      design, population characteristics, CBD doses, treatment duration, 
      co-medications, and AEs were compiled. RESULTS: A total of 51 reports were 
      included. Most studies investigated CBD efficacy and safety in neurological 
      conditions, such as treatment-resistant epilepsies, although a growing number of 
      studies are focusing on specific psychopathological conditions, such as substance 
      use disorders, chronic psychosis, and anxiety. Most studies report mild or 
      moderate severity of AEs. The most common AEs are diarrhea, somnolence, sedation, 
      and upper respiratory disturbances. Few serious AEs have been reported, 
      especially when CBD is co-administered with other classes of drugs, such as 
      clobazam and valproate. CONCLUSION: Clinical data suggest that CBD is well 
      tolerated and associated with few serious AEs at therapeutic doses both in 
      children and adults. However, interactions with other medications should be 
      monitored carefully. Additional data are needed to investigate CBD's long-term 
      efficacy and safety, and CBD use in medical conditions other than epilepsy 
      syndromes.
CI  - Copyright(c) Bentham Science Publishers; For any queries, please email at 
      epub@benthamscience.net.
FAU - Madeo, Graziella
AU  - Madeo G
AD  - Clinical Center of Neurology and Psychiatry, Brain&Care Group, Rimini, Italy.
FAU - Kapoor, Ashita
AU  - Kapoor A
AD  - Unit of Forensic Toxicology, Section of Legal Medicine, Department of Biomedical 
      Sciences and Public Health, Marche Polytechnic University, Ancona, Italy.
FAU - Giorgetti, Raffaele
AU  - Giorgetti R
AD  - Unit of Forensic Toxicology, Section of Legal Medicine, Department of Biomedical 
      Sciences and Public Health, Marche Polytechnic University, Ancona, Italy.
FAU - Busardo, Francesco Paolo
AU  - Busardo FP
AD  - Unit of Forensic Toxicology, Section of Legal Medicine, Department of Biomedical 
      Sciences and Public Health, Marche Polytechnic University, Ancona, Italy.
FAU - Carlier, Jeremy
AU  - Carlier J
AD  - Unit of Forensic Toxicology, Section of Legal Medicine, Department of Biomedical 
      Sciences and Public Health, Marche Polytechnic University, Ancona, Italy.
LA  - eng
PT  - Journal Article
PT  - Systematic Review
PL  - United Arab Emirates
TA  - Curr Neuropharmacol
JT  - Current neuropharmacology
JID - 101157239
RN  - 19GBJ60SN5 (Cannabidiol)
RN  - 0 (Anticonvulsants)
SB  - IM
MH  - Child
MH  - Adult
MH  - Humans
MH  - *Cannabidiol/adverse effects
MH  - *Epilepsy/drug therapy
MH  - Anxiety
MH  - Anticonvulsants/adverse effects
PMC - PMC10556379
OTO - NOTNLM
OT  - Cannabidiol
OT  - adverse event
OT  - anxiety
OT  - clinical study
OT  - psychosis
OT  - toxicity
OT  - treatment-resistant epilepsy
COIS- The authors declare no conflict of interest, financial or otherwise.
EDAT- 2023/03/23 06:00
MHDA- 2023/09/11 06:42
PMCR- 2024/03/01
CRDT- 2023/03/22 08:03
PHST- 2022/12/04 00:00 [received]
PHST- 2023/01/15 00:00 [revised]
PHST- 2023/01/16 00:00 [accepted]
PHST- 2023/09/11 06:42 [medline]
PHST- 2023/03/23 06:00 [pubmed]
PHST- 2023/03/22 08:03 [entrez]
PHST- 2024/03/01 00:00 [pmc-release]
AID - CN-EPUB-130324 [pii]
AID - CN-21-2323 [pii]
AID - 10.2174/1570159X21666230322143401 [doi]
PST - ppublish
SO  - Curr Neuropharmacol. 2023;21(11):2323-2342. doi: 
      10.2174/1570159X21666230322143401.